An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Completed
Tillotts Pharma AG
Phase 3
2002-09-01
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission
in subjects with Crohn's Disease who are responding to steroid induction therapy.
Patient safety and quality of life will also be monitored throughout the study.
The primary objective of this study is to assess the ability of EpanovaTM Soft Gelatin
Capsules at a total daily dose of 4g (4x 1g capsules) to maintain remission (Crohn's Disease
Activity Index CDAI < 150) in CD patients in whom remission, stable for at least three months
and no longer than one year, has been induced by corticosteroids, azathioprine/6-MP,
methotrexate, 5-ASA or antibiotics.
Secondary objectives are to assess the:
efficacy of Epanova versus placebo by Crohn's Disease Activity Index (CDAI), Investigator and
Subject Global Ratings, employment status and use of CD related medical visits in subjects
with CD in remission
safety and tolerability of Epanova
ability of Epanova to maintain the quality of life of CD patients in remission
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
Completed
Radiant Research
Phase 2
2010-09-01
The objectives of this study are to compare the relative bioavailabilities of
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of
Epanova or Lovaza during periods of high- and low -fat consumption.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
